The Immune Monitoring Core (Core C) will be comprised of technologies and services offered by two service laboratories within the laboratories of this program project: the Lyerly/Clay lab and the Immune Reconstitution Facility (Chao Lab). Core C will routinely provide investigators with high quality, state-of-the-art flow cytometry, cellular monitoring by ELIspot, proliferation, and lysis assays, protein array, and gene expression assay support for their basic and applied research efforts. In addition to providing these services, the Core will be instrumental in developing new methodologies and making them available to the P-O1 investigators. Administrative oversight for the Core will institute a charge-back mechanism to remain revenue neutral. The five goals of the Immune Monitoring Core are: 1) Provide state-of-the-art, multi-color, fluorescence activated cell sorting and analytical support for basic or translational research conducted by the P-O1 investigators. This includes high-speed sorting and multi-color analysis of cellular subsets. Assays are available for surface and intracellular marker analysis of mouse, rat, rhesus, baboon and human cells. 2) Provide state-of-the-art ELISpot, ELISA, proliferation and lysis assays for the functional characterization of antigen-specific T cell responses and anti-viral immunity. 3) Provide targeted multiplex protein array profiling of mouse and human samples, using our BioPlex bead array reader (BioRad) and Luminex bead technology. 4) Provide quantitative real-time-PCR multiplex gene expression analysis to investigators. Specific assays include T cell receptor excision circle quantification in mice and humans (qPCR), and simultaneous quantification of up to four target mRNA species in a single sample (qRT-PCR). 5) Provide state-of-the-art patient sample handling and assessment of immune responses, with standardized SOPs, quality assurance and quality control practices to monitor assay performance and validate data quality. By educating and working in collaboration with the P-O1 scientific program users, we will develop and optimize their specific assays and effectively utilize the state-of-the-art instrumentation offered by the Core.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA047741-19
Application #
8381936
Study Section
Special Emphasis Panel (ZCA1-RPRB-J)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
19
Fiscal Year
2012
Total Cost
$188,306
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
MacDonald, Kelli Pa; Blazar, Bruce R; Hill, Geoffrey R (2017) Cytokine mediators of chronic graft-versus-host disease. J Clin Invest 127:2452-2463
MacDonald, Kelli P A; Hill, Geoffrey R; Blazar, Bruce R (2017) Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood 129:13-21
Du, Jing; Paz, Katelyn; Flynn, Ryan et al. (2017) Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-? production. Blood 129:2570-2580
Du, Jing; Paz, Katelyn; Thangavelu, Govindarajan et al. (2017) Invariant natural killer T cells ameliorate murine chronic GVHD by expanding donor regulatory T cells. Blood 129:3121-3125
Rowland, Christopher R; Colucci, Lina A; Guilak, Farshid (2016) Fabrication of anatomically-shaped cartilage constructs using decellularized cartilage-derived matrix scaffolds. Biomaterials 91:57-72
Flynn, Ryan; Paz, Katelyn; Du, Jing et al. (2016) Targeted Rho-associated kinase 2 inhibition suppresses murine and human chronic GVHD through a Stat3-dependent mechanism. Blood 127:2144-54
Sung, Anthony D; Sung, Julia A M; Thomas, Samantha et al. (2016) Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial. Clin Infect Dis 63:999-1006
Brennan, Todd V; Lin, Liwen; Brandstadter, Joshua D et al. (2016) Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation. J Clin Invest 126:207-19
Tuchman, Sascha A; Bacon, Wendi A; Huang, Li-Wen et al. (2015) Cyclophosphamide-based hematopoietic stem cell mobilization before autologous stem cell transplantation in newly diagnosed multiple myeloma. J Clin Apher 30:176-82
Brennan, Todd V; Rendell, Victoria R; Yang, Yiping (2015) Innate immune activation by tissue injury and cell death in the setting of hematopoietic stem cell transplantation. Front Immunol 6:101

Showing the most recent 10 out of 129 publications